1 February 2022

ASX Announcement

Nasodine COVID-19 trial receives SAHPRA approval

Firebrick Pharma Limited (ASX:FRE) (Company or **Firebrick)** announced today that its planned clinical trial of Nasodine Nasal Spray (povidone-iodine 0.5%) in COVID-19 patients in South Africa, had received approval to proceed from the South African Health Products Regulatory Authority (SAHPRA).

The trial is titled: "Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients by the use of Nasodine® (povidone-iodine 0.5%) Nasal Spray." It is intended to demonstrate that frequent, repeated application of Nasodine Nasal Spray ("Nasodine") in COVID-19 subjects who are RAT-positive, leads to reduction or elimination of nasal shedding of the Sars-CoV-2 virus.

The SAHPRA approval specifically allows Firebrick Pharma to import Nasodine into South Africa for the trial and to administer the product to patients during the trial, according to the trial protocol submitted to SAHPRA.

As noted in the Company's prospectus (section 2.4.4(b)), prior to commencing the trial the Company will also need approval from the local clinical Ethics Committee, which has been applied for but has yet to be received.

This announcement has been authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antiviral agent. The company's name comes from the colour of povidone-iodine (hex colour #b22222, called 'Firebrick'). The company owns numerous granted and pending patents, including a core patent that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. This patent has already been granted in Australia, US, Europe and several other countries.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com